DWD has received consulting fees from Amgen, Atria, CapiThera, Cerecin, Ceruvia Lifesciences, CoolTech, Ctrl M, Allergan, AbbVie, Biohaven, GlaxoSmithKline, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Genentech, Nocira, Perfood, Praxis, AYYA Biosciences, Revance, and Pfizer; honoraria from the American Academy of Neurology, Headache Cooperative of the Pacific, Canadian Headache Society, MF Med Ed Research, Biopharm Communications, CEA Group Holding Company (Clinical Education Alliance), Teva (speaking), Amgen (speaking), Eli Lilly (speaking), Lundbeck (speaking), Pfizer (speaking), Vector Psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin, Medlogix Communications, Medica Communications, MJH Lifesciences, Miller Medical Communications, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, and Cambridge University Press; non-profit board membership for American Brain Foundation, American Migraine Foundation, ONE Neurology, Precon Health Foundation, International Headache Society Global Patient Advocacy Coalition, Atria Health Collaborative, Arizona Brain Injury Alliance, and Domestic Violence HOPE Foundation/Panfila; research support from the Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Henry Jackson Foundation, and the Patient Centered Outcomes Research Institute; has stock options with Aural Analytics, ExSano, Palion, Man and Science, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, King-Devick Technologies, EigenLyfe, AYYA Biosciences,Cephalgia Group, and Atria Health; is a shareholder with Axon Therapeutics, Matterhorn, and Ontologics; is on the board of directors for Axon Therapeutics, King-Devick Technologies, and Cephalgia Group; has patent 17189376.1-1466:v (title: Onabotulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis; non-royalty bearing); and has a patent application submitted for Synaquell (Precon Health). All other authors declare no competing interests.